Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Ramasamy, PathmaMurphy, Conor C
Clynes, Martin
Horgan, Noel
Moriarty, Paul
Tiernan, Damien
Beatty, Stephen
Kennedy, Susan
Meleady, Paula
Affiliation
Royal College of Surgeons Ireland, Stephen's Green, Dublin 2, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Collins Avenue, Glasnevin, Dublin 9, Ireland. Electronic address: Pathma.Ramasamy@dcu.ie.Issue Date
2014-01Keywords
CANCEREYE DISORDER
MeSH
HumansMelanoma
Proteomics
Tumor Markers, Biological
Uveal Neoplasms
Metadata
Show full item recordCitation
Ramasamy, P. et al., 2014. Proteomics in uveal melanoma. Experimental Eye Research, 118 (1), pp 1-12Journal
Experimental eye researchDOI
10.1016/j.exer.2013.09.005PubMed ID
24056206Abstract
Uveal melanoma is the most common primary intraocular malignancy in adults, with an incidence of 5-7 per million per year. It is associated with the development of metastasis in about 50% of cases, and 40% of patients with uveal melanoma die of metastatic disease despite successful treatment of the primary tumour. The survival rates at 5, 10 and 15 years are 65%, 50% and 45% respectively. Unlike progress made in many other areas of cancer, uveal melanoma is still poorly understood and survival rates have remained similar over the past 25 years. Recently, advances made in molecular genetics have improved our understanding of this disease and stratification of patients into low risk and high risk for developing metastasis. However, only a limited number of studies have been performed using proteomic methods. This review will give an overview of various proteomic technologies currently employed in life sciences research, and discuss proteomic studies of uveal melanoma.Item Type
ArticleLanguage
enISSN
1096-0007ae974a485f413a2113503eed53cd6c53
10.1016/j.exer.2013.09.005
Scopus Count
Collections
Related articles
- Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not.
- Authors: Linge A, Kennedy S, O'Flynn D, Beatty S, Moriarty P, Henry M, Clynes M, Larkin A, Meleady P
- Issue date: 2012 Jul 9
- Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery.
- Authors: Pardo M, Dwek RA, Zitzmann N
- Issue date: 2007 Apr
- Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss.
- Authors: Coupland SE, Vorum H, Mandal N, Kalirai H, Honoré B, Urbak SF, Lake SL, Dopierala J, Damato B
- Issue date: 2010 Jan
- iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors.
- Authors: Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R, Singh AD
- Issue date: 2015
- Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
- Authors: All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O
- Issue date: 2002 Jan